With thousands of press releases published each week, it can be difficult to keep up with everything on . To help healthcare journalists and consumers stay on top of the week's most newsworthy and ...
With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...
HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...
The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...
The FDA has approved popular antiobesity drug Ozempic to help protect patients with type 2 diabetes from kidney disease.
A new study suggested that users of GLP-1 receptor agonist medications like Ozempic spend less money at the grocery store: what dietitians want you to know.
The FDA has approved Ozempic to reduce kidney failure risk in people with type 2 diabetes and chronic kidney disease. Studies ...
The approval is based on results from the Phase III FLOW trial demonstrating Ozempic reduced the risk of severe kidney outcomes by 24% compared to placebo, including kidney failure, reduction in ...
The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback